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In vivo X-ray fluorescence (XRF) measurement of bone lead concentration (XRF) has emerged as an important technique for future epidemiological
studies of long-term toxicity. Several issues germane to epidemiologic methodology need to be addressed, however. First, sources of variability in
measurements of bone lead need to be quantified, including imprecision related to the physical measurement itself and the variability of lead deposi-
tion over the two main compartments of bones (cortical vs. trabecular) and within each compartment. Imprecision related to the physical measure-
ment can be estimated for each individual measurement based on the variability of the signal and background. Second, approaches to low-level data
need to be debated. We argue for using the minimal detection limit (MDL) to compare instruments and interpret individual measurements; how-
ever, with regard to epidemiologic studies, we would abandon the MDL in favor of using all point estimates. In analyses using bone lead as an inde-
pendent variable, statistical techniques can be used to adjust regression estimates based on estimates of measurement uncertainty and bone lead
variability. Third, factors that can be expected to modify the relationship between bone lead and toxicity such as gravida history, endocrinological
states, nutrition, and other important influences on bone metabolism, need to be identified and measured in epidemiologic studies. By addressing
these issues, investigators will be able to maximize the utility of XRF measurements in environmental epidemiologic studies. - Environ Health
Perspect 103(Suppl 1):105-110 (1995)
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Introduction
Lead is a familiar topic to all environmental
scientists to some degree. Perhaps the most
studied ofall toxins and the subject ofhun-
dreds of scientific publications each year,
attention to lead has recently increased yet
again. Most responsible has been a spate of
longitudinal epidemiologic studies indicat-
ing an adverse effect of lead on indices of
neurobehavioral function and intelligence
at low levels of exposure, a revelation that
led to a recent report to Congress (1), a
revised health advisory by the Centers for
Disease Control (2), and a flurry of atten-
tion from the media.
Despite this activity, there remains a
host of important unknowns surrounding
lead toxicity, particularly regarding the
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long-term effects ofchronic low-level expo-
sure and methods for identifying individu-
als who are at risk. Central to these issues is
the realization that lead accumulates in the
skeleton and remains there, long after expo-
sure may have decreased. Whereas levels of
lead in blood, the most commonly used
indicator ofinternal lead exposure, tend to
decrease rapidly with an average half-life of
about one month (3), levels oflead in bone
have a half-life ofyears to decades (4,5). In
children, some 70 to 80% of total body
lead burden is contained in bone; the figure
rises to 90 to 95% in adults (6,7). Among
the considerations this phenomenon raises
are: a) are levels of lead in bone a useful
indicator ofprior exposure to lead; and b)
are bone lead stores themselves a risk factor
for future toxicity?
These considerations would remain aca-
demic ifit were not for the recent develop-
ment of X-ray fluorescence (XRF)
techniques for in vivo measurement of
bone lead stores. The purpose ofthis article
is to briefly reviewXRF and discuss consid-
erations that are specific to environmental
epidemiologic research.
In VivoX-ray Fluorescence
Technical aspects of in vivo XRF, under
steady development for over 15 years by
investigators in the United Kingdom,
Sweden, Australia, and the United States,
have been reviewed in detail elsewhere
(8-10). In short, XRF instruments utilize
low-level gamma radiation to provoke the
emission of fluorescent photons from the
target area ofa test subject's anatomy. The
photons are detected and counted over the
wavelength spectrum (Figure 1), from
which the characteristic emissions of lead
are then carefully extracted. Measurements
are noninvasive, painless, and require very
little radiation exposure (11).
Two main XRF techniques exist: L-
XRF, which uses weakly-penetrating radia-
tion and concentrates on the emissions
from L-shell electrons (12); and K-XRF,
which uses radiation that penetrates bone
more deeply and concentrates on K-shell
electron emissions. The latter technique
has a number ofvariations with respect to
the radioactive isotopes used to generate
the source radiation, the geometry of the
source-detector arrangement, software,
electronics hardware, and the anatomical
target(s) chosen for the measurement. A
comparison ofL- and K-XRF can be found
elsewhere (6).
Our group chose to use a K-XRF
instrument with a 109Cd source in a back-
scatter geometry to measure bones of the
lower leg (Figure 2). The number of lead
fluorescent photons is compared with the
Environmental Health Perspectives 105Energy (keV)
8s
Figure 1. A simple in vivo bone lead measurement spectrum (112 mcg Pb/g phantom made of plaster-of-paris)
(10).
number ofphotons from the coherent scat-
ter signal (which comes principally from
calcium hydroxyapatite), resulting in pg of
lead per g of bone mineral (jg/g) as the
unit of measurement. This method of nor-
malization renders the measurement insen-
sitive to variations in bone shape, size,
density, and histomorphometry, overlying
tissue thickness, and movement (13).
Validation studies comparing measure-
ments from an instrument with this design
against chemical analysis in cadaver studies
have shown a high degree of accuracy
(14-16).
Our instrument has two features that
are adapted specifically to large epidemio-
logic studies. The software that runs the
instrument and analyzes the resultant spec-
tra is algorithm-driven, allowing the instru-
ment to be operated by a trained
technician rather than a physicist (17). In
addition to measuring bone lead concen-
tration, our instrument estimates each
individual measurement's uncertainty
(equivalent to 1 standard deviation of
replicate measurements) based on analyses
ofthe characteristic X-rays (12), which cre-
ates the potential to adjust epidemiologic
analyses for individual measurement error.
Measurement uncertainty tends to increase
with obesity (thicker overlying tissue) and
lower bone density (18).
Existing Studies of
Bone Lead Using in Vivo XRF
Most investigations have so far been con-
ducted with K-XRF instruments in surveys
of workers employed in factories with
known lead exposure (2,19-21), in studies
comparing lead burden estimated by XRF
with lead burden estimated by chelation
and cumulative indices of blood lead
(22-24), and in pilot studies of control
subjects with no known lead exposure
(10,12,25). One group ofinvestigators has
been using an L-X-ray fluorescence tech-
nique to measure lead burden in children
(26); the same investigators also conducted
a survey of lead burden among factory
workers (27).
These studies have confirmed that the
kinetics ofXRF-measured bone lead are
quite unlike blood lead. Bone lead increases
in proportion to the level and duration of
exposure, and diminishes very slowly once
exposure ceases. A high correlation is seen
between XRF-measured tibia lead and a
time-integrated blood lead index (16,21).
Heterogeneity among bone sites and bone
types (cortical vs trabecular) seems to exist,
with cortical bones such as the tibia
exhibiting very slow kinetics as opposed to
the faster turnover oftrabecular bones such
as the patella and calcaneus (18,21). After
treatment with the chelating agent calcium
disodium edetate, bone lead levels drop
slowly (28) if at all (21), as opposed to
blood lead levels, which decrease more
rapidly.
Investigations using XRF that attempt
to correlate bone lead levels with indices of
health are just beginning to appear in the
literature. Two cross-sectional investiga-
tions did not find any relationship between
Figure 2. A K-X-ray flourescence instrument (ABIO-
MED, Inc., Danvers, MA) taking a mid-tibial measure-
mentfrom a research subject (15).
XRF-measured bone lead and indicators of
kidney function, including several sensitive
markers of early tubular and glomerular
damage such as urinary N-acetylgu-
cosaminidlase activity, retinol binding pro-
tein, urinaryP2-microglobulin, and urinary
albumin (29,30).
The Future of K-XRF and
Epidemiology: Methodology
The development of in vivo XRF has in
essence expanded the pool of biologic
markers ("biomarkers") for lead. Others
have traditionally included measurement of
lead in blood, hair, urine, and teeth;
chelatable lead; erythrocyte protoporphyrin
in blood; and porphyrin cogeners and
aminolevulinic acid dehydratase in blood
and urine (Table 1). Under classification
schemes designed to define biologic mark-
ers, the most apparent position of bone
lead is as a biologic marker ofinternal dose
(Table 1).
In addition, bone lead may also be able
to serve as a biologically effective marker of
dose (31) that is specific to skeletal tissue.
Lead is toxic to osteoblasts in vitro (32)
and lead exposure has been associated with
decreased skeletal growth, as manifested by
height and chest circumference (33). Lead
exposure has also been associated with
lower indices of red cell production, even
at relatively low blood lead levels (34).
Since hematopoiesis occurs in bone mar-
row, it is possible that bone lead would be
a more accurate dose marker than blood
lead for this form oftoxicity.
More epidemiologic research that tests
the ability ofXRF-measured bone lead to
serve as a biologic marker for both occupa-
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Table 1. Examples of biologic markers for monitoring lead and their characteristics.
Biologic markers Half-life
Biologic markers of int
Blood lead
Urine lead
Hair lead
Nail lead
Tooth lead
Bone lead
Chelatable lead
Comments regarding use as indicator ofaccumulated lead exposure
eternal dose
Weeks to months
Weeks Dependent on urine flow
Months Large intraindividual variability; prone to external contamination or
leeching
Months Prone to external contamination; kinetics uncertain
Decades to oo Must await shedding of deciduous tooth, isolate circumpulpal dentine;
in vivomeasurement ofwhole tooth lead available, but of uncertain
utility
Years to decades Cortical bone has long half-life; trabecular bone has shorter half-life
Years Involves injection and timed collection of urine; represents "chelatable"
compartment of lead found mostly in softtissue, partly in bone
Biologically effective dose markers
Bone lead Years to decades
Biologic response marker
Erythrocytic Weeks to months
protoporphyrin
Erythrocytic 5-ALAD Weeks
UrinaryALAD,
coproporphyrins
Weeks
May be related to abnormal skeletal development and/or hematopoiesis
(untested)
Level increases due to lead's inhibition of hematopoiesis; integrates
exposure over several months; sensitivity poorfor sustained mild-to-
moderate elevations of blood lead (25-40 mcg/dl); increased levels
also seen in iron deficiency
Activity inhibited by lead but also by other metals, e.g. methylmercury,
and by ethanol intoxication
Levels also increased in certain hepatic diseases
ALAD, aminolevulinic acid dehydratase. aThe amount of lead found in urine over a defined time period following
injection ofcalcium disodium ethylenediamine-tetraacetate, a chelating agent.
tionally exposed populations and low-level
toxicity is eagerly awaited (35,36).
Although several such studies are underway
and more are anticipated, several method-
ologic issues need to be addressed to maxi-
mize the utility ofXRF measurements in
epidemiologic studies.
One set of issues relates to technical
aspects ofXRF measurements: precision,
calibration, and intercalibration. A recent
workshop that gathered investigators in
this field to share experiences and innova-
tions has helped address these concerns by
identifying design and equipment improve-
ments that enhance measurement precision
(37) and by developing criteria for the
construction ofphantom targets that can
be used and exchanged as part ofa calibra-
tion/intercalibration protocol (42).
A separate set of issues, however, arises
from the epidemiologist's perspective.
These can be roughly grouped into three
categories: understanding and quantifying
sources ofvariability in XRF measurements
ofbone lead; dealing with the concepts of
minimum detectable limits and measure-
ment error; and identifying and measuring
cofactors that are likely to modify the rela-
tionship between bone lead and toxicity.
Sources ofVariability in
Measurements ofBone
Sources ofvariability in measurements of
bone lead contribute to "noise" in studies
ofthe relationship between bone lead and
toxicity. Since methods have been devel-
oped for adjusting analyses for the effect of
noise (see below), it is important to identify
and quantify to the extent feasible these
sources ofvariability. Chiefamong them is
imprecision related to the physical mea-
surement itself. Although technical improve-
ments promise to decrease imprecision
significantly, some amount will always
remain. Various host factors contribute to
increased imprecision. Increased soft tissue
overlying the bone being measured (which,
in turn, is higher among females and also
may be related to obesity and edematous
states) attenuates incident radiation and the
returning signal, thereby reducing preci-
sion. The thinner or less mineralized bones
ofchildren or adults with osteoporosis or
osteomalacia provide less matrix for the cal-
cium component of K-XRF measurement,
therebycontributing to imprecision.
Imprecision related to the physical
measurement can be quantified by gauging
the strength of the returning signal. For
each measurement, K-XRF instruments
derive an estimate of the measurement
uncertainty that reflects the variance both
in the X-ray signal and in the background
underlying the signal; in effect, it is equiv-
alent to the standard deviation one would
expect from multiple measurements (34).
Although this parameter itself needs fur-
ther research to validate its accuracy, par-
ticularly under in vivo conditions rather
than with phantoms, it promises to
significantly assist the epidemiologist (see
next section).
Another source ofvariability is intra-
individual variability in the distribution of
lead in the skeleton. There is clear evidence
from both autopsy studies and multiple-
site XRF studies that bone lead kinetics
dichotomize between a cortical bone com-
partment and a trabecular bone compart-
ment (2,17,21,29). This can be taken into
account by measuring both a predomi-
nantly cortical bone (i.e., the mid-tibia)
and a predominantly trabecular bone (e.g.,
the calcaneus or patella) in future XRF
studies. Our group has favored the patella
over the calcaneus as a predominantly tra-
becular bone, since it seems to have more
bone mass and therefore affords better
measurement precision.
In addition, however, there is evidence
that skeletal lead deposition has significant
within-compartment variability. Wittmers
et al. (39) found that the coefficient of
variation for chemically measured bone
lead concentrations ofsamples taken from
multiple sites on the tibia from a single
individual was 14%. In another study that
examined six bone sites and conducted sep-
arate chemical analyses of cortical bone
separated from trabecular bone, the bone
lead concentration of the mid-tibia (a site
frequently targeted in XRF studies) was
found to have a correlation coefficient of
0.55 in comparison to the mean of the
bone-lead concentrations from the cortical
segments ofthe other five sites (40). A sin-
gle XRF bone lead measurement is there-
fore likely to be only partly representative
ofskeletal lead burden, even within its own
compartment.
Thus, in studies using XRF, the envi-
ronmental epidemiologist will be con-
fronted with XRF data with several sources
ofvariability. One source, measurement
uncertainty, can be individually quantified.
The other, variability ofskeletal lead distri-
bution, can be reduced by measuring two
or more bone sites; however, some residual
variability will no doubt remain. These
sources ofvariability will reduce both the
power with which an association can be
made between bone lead and a toxicologi-
cal outcome, and the magnitude of the
effect estimate once an association has been
made (41).
MinimalDetectableLimits,
MeasurementError, and
AdjustmentforMeasurementError
Classical laboratory practice calls for calcu-
lation of a minimum detectable limit
(MDL). Measurements that fail to exceed
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this value are put into a single category and
are assumed to be indistinguishable from
zero. With regard to in vivo XRF, physi-
cists have defined the MDL as 2x standard
deviation of net peak area counts (42), 3x
standard deviation of background counts
(43), or more recently, 2x the median of
the uncertainty values (a function of both
the peak and background count standard
deviations)(44). Although analysis of in
vivo XRF data is still in its infancy, several
statistical methods could be borrowed from
environmental pollution research for
assigning a value to below-MDL measure-
ments in order to retain them in continous
variable analyses (45,46).
In vivoXRF data are quite distinct from
most laboratory data, however. Due to the
random nuture ofradiation interaction and
the calibration procedure, XRF instru-
ments provide an unbiased point estimate
of lead concentration that may be zero or
negative. In other words, if a bone with
absolutely no lead is being measured multi-
ple times by in vivo XRF, the measure-
ments will oscillate around zero. Negative
results obviously have no intrinsic mean-
ing; they are negative only because the true
bone lead concentration is close to zero and
there is error associated with the measure-
ment. In addition, as mentioned above,
each in vivoXRF measurement is accompa-
nied by an estimate ofthe uncertainty asso-
ciated with that measurement.
Certainly, from a clinical perspective, i.e.,
the interpretation ofany given individual's
single K-XRF measurement, it is important
to rely on the concept ofan MDL; it defines
a level below which most measurements ofa
true zero will fall. The MDL is also an
important parameter for comparing the pre-
cision ofvarious XRF instruments.
From the epidemiologist's perspective,
however, useful information would be lost
if, in the analysis of in vivo XRF data, an
MDL were used to censor data or amalga-
mate low-level bone lead estimates into a
single category. It is preferable to use all the
point estimates, even ifzero or below zero,
in conjunction with the individual esti-
mates of uncertainty. In essence, the indi-
vidual estimates of measurement
uncertainty carry information about the
true bone lead concentrations. For exam-
ple, for two identical and positive bone
lead measurements falling below the MDL,
the reading with the smaller estimate of
measurement uncertainty will have a higher
chance of corresponding to a true bone
lead concentration greater than zero. We
can use the estimate of measurement
uncertainty together with the actual bone
lead reading to modify the standard regres-
sion analyses when bone lead is used as a
predictorvariable.
Ignoring the error of the K-XRF mea-
surement in ordinary least squares analyses
produces estimates of the slope that are
biased towards the null (47,48). The
degree ofattentuation in the slope depends
on the magnitude ofthe uncertainty ofthe
measurement error relative to the variabil-
ity ofthe true bone lead values in the data.
IfX is the quotient between the variance of
the predictor over the sum ofthe predictor
variance and the average measurement
error variance, an analysis using bone lead
measured as a predictor would produce
estimates of the true slope attenuated by a
factor ofX. That is, the estimated slope is X
times the true slope.
We can obtain an estimate of the
coefficient ofattenuation (X) using the indi-
vidual measurement error estimates pro-
duced by the K-XRF instrument, thus
correcting the standard ordinary least
squares estimates. Roughly speaking, the
adjusted estimated slope is equal to the
ordinary least squares slope divided by the
coefficient of attenuation. We can also use
the estimate ofmeasurement uncertainty to
estimate the standard error ofthe adjusted
regression coefficients. Although the esti-
mated slope is revised upward, the extra
variability of the adjusted slope estimate
generally results in reduced power for test-
ing the null hypothesis that the slope is
equal to zero.
Modifiers ofBoneLeadandToxicity
Finally, it is important for the epidemiolo-
gist to anticipate factors that may modify
the relationship between bone lead and
toxicity. As a biologic marker of internal
dose, the bioavailability of bone lead for
organ toxicity outside ofbone is theoreti-
cally dependent on processes that affect
bone metabolism, and, therefore, the liber-
ation oflead from bone.
Ofparticular interest are pregnancy,
lactation, and osteoporosis. For example,
blood lead concentration has been found to
be elevated in postmenopausal women in
comparison to premenopausal women,
even after controlling for age, calcium
intake, and other variables potentially
related to external lead exposure and min-
eral metabolism (49). The extent of the
elevation among the postmenopausal
women was also higher among those who
were nulliparous, thus providing indirect
evidence that increased mobilization of
lead from bone can occur during the osteo-
porosis associated with menopause and the
bone demineralization of pregnancy.
Individual case reports have provided evi-
dence that lead stored from exposures
many years previously can be mobilized
during pregnancy (50,51).
Attention must be paid to other
influences of bone metabolism that have
been shown to affect lead kinetics. A case
was recently reported ofa woman with ele-
vated K-XRF measured bone stores who
experienced marked elevations of blood
lead when she developed hyperthyroidism,
which is accompanied by greatly increased
bone turnover (52). Experimental therapy
to increase bone mass and surgical treat-
ment of hyperparathyroidism were both
found to be independently associated with
reductions in blood lead (53). It is likely
that other endocrinologic, nutritional, and
miscellaneous factors that affect bone
metabolism also affect lead mobilization.
For example, hypercorticolism from
endogenous overproduction states or the
exogenous administration ofsteroid med-
ications is known to enhance bone dem-
ineralization (54). Conversely, high levels
ofdietary calcium and regular exercise are
known to inhibit bone demineralization
(55).
These phenomena make it advisable for
an environmental epidemiologist to collect
data on parity, nutrition, and endocrino-
logic factors that might modify the rela-
tionship between XRF-measured bone lead
and measures ofoutcome.
Conclusion
In vivo XRF promises to add significantly
to our knowledge of lead toxicity by pro-
viding a biologic marker oflead accumula-
tion. To optimize the use of this biologic
marker in epidemiologic studies, it will be
important to increase instrument precision,
develop intercalibration protocols, estimate
variability in skeletal lead distribution, vali-
date the individual estimates of measure-
ment uncertainty, apply techniques for
adjusting analyses for measurement uncer-
tainty, and measure factors that may mod-
ify bone lead-outcome relationships.
Even as this research progresses, how-
ever, it may be important to assess other
potential biologic markers, particularly
those that might serve as accurate biologic
markers ofeffective lead dose. By so doing,
we will be able to better bridge the
domains oftoxicology and epidemiology to
shed more light on the ultimate effects of
this remarkable toxin.
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